title: Taking peritoneal dialysis beyond the year 2000.
abstract: Over the past 25 years, peritoneal dialysis (PD) has steadily improved so that now its outcomes, in the form of patient survival, are equivalent to, and at times better than, those for hemodialysis. We now have a better understanding of the pathophysiology of peritoneal membrane function and damage and the importance of appropriate prescription to meet agreed-upon targets of solute and fluid removal. In the next millennium, greater emphasis will be put on prescription setting and subsequent monitoring. This will entail an increase in automated PD, especially for lifestyle reasons as well as for patients with a hyperpermeable peritoneal membrane. To improve outcomes, dialysis should be started earlier than is currently the case. It is easy to do this with PD, where an incremental approach is made easier by the introduction of icodextrin for long-dwell PD. In the future, solutions will be tailored to be more biocompatible and to provide improved nutrition and better cardiovascular outcomes. Finally, economic considerations favor PD, which is cheaper than in-centre hemodialysis. Thus, for many, PD has become a first-choice therapy, and with further improvements this trend will continue.
authors.affiliation: Department of Renal Medicine, Manchester Royal Infirmary, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Gokal
mesh_terms: D003362:Cost-Benefit Analysis; D015314:Dialysis Solutions; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D007677:Kidney Function Tests; D010530:Peritoneal Dialysis / Q000592:standards / Q000706:statistics & numerical data / Q000639:trends*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000592:standards / Q000706:statistics & numerical data / Q000639:trends*; D006435:Renal Dialysis / Q000639:trends; D016019:Survival Analysis
chemical_list: D015314:Dialysis Solutions